Reaction

Weight Bearing Difficulty reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,667 reports · 47 co-occurring drugs

As of the last recalculation, Weight Bearing Difficulty appears in 2,667 FAERS reports alongside 47 co-occurring drug terms. The strongest observed disproportionality signal is SEVOFLURANE (PRR 18.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Sevoflurane	20	18.9	19.0
Ciprofolxacin	122	13.9	13.9
Ciprofloxacin Tablets	122	13.9	13.9
Ciprofloxacin Hydrochloride	154	13.1	13.1
Ciprofloxacin	144	12.9	12.9
Risedronate Sodium	35	8.9	8.9
Alendronate Sodium Tablet	20	8.5	8.5
Ciprofloxacin Hydrochloride And Hydrocortisone	22	8.3	8.3
Levofloxacin	62	8.2	8.2
Levofloxacin In 5% Dextrose	62	8.2	8.2
Asfotase Alfa	10	7.8	7.8
Fentanyl Citrate	15	6.6	6.6
Infliximab-Dyyb	23	6.2	6.2
Bumetanide	20	5.9	6.0
Teriparatide	78	5.5	5.5
Zoledronic Acid	27	5.3	5.3
Timolol	8	5.2	5.2
Propofol	23	4.9	4.9
Sulfasalazine	48	4.9	4.9
Peginterferon Beta-1A	8	4.8	4.8
Brinzolamide	5	4.5	4.5
Siponimod	5	4.4	4.4
Multivitamin	26	4.1	4.1
Upadacitinib	40	3.9	3.9
Teriflunomide	21	3.6	3.6
Carbidopa And Levodopa	20	3.3	3.3
Dalfampridine	30	3.3	3.3
Diroximel Fumarate	5	3.3	3.3
Vibegron	3	2.9	2.9
Inclisiran	3	2.9	2.9
Ofatumumab	12	2.8	2.8
Diclofenac Potassium, Film Coated	3	2.8	2.8
Diclofenac Potassium Tablets	3	2.8	2.8
Denosumab	69	2.7	2.7
Interferon Beta-1A	65	2.7	2.7
Risankizumab-Rzaa	27	2.6	2.6
Cortisone Acetate	4	2.5	2.5
Sacubitril And Valsartan	33	2.2	2.2
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	5	2.2	2.2
Abaloparatide	8	2.1	2.1
Drospirenone And Ethinyl Estradiol	11	1.9	1.9
Dimethyl Fumarate	30	1.9	1.9
Natalizumab	43	1.9	1.9
Pimavanserin Tartrate	13	1.8	1.8
Relugolix	5	1.7	1.7
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	5	1.3	1.3
Evolocumab	18	0.9	0.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.